This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sitosterolemia Metabolism (STAIR7002)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
University of Manitoba Identifier:
First received: April 16, 2012
Last updated: March 9, 2016
Last verified: December 2015
Ezetimibe has become the treatment choice for patients with sitosterolemia. Ezetimibe is an inhibitor of cholesterol absorption from the gastrointestinal tract. The purpose of this study is to determine if ezetimibe improves whole body plant sterol and cholesterol homeostasis.

Condition Intervention
Sitosterolemia Drug: Ezetimibe

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe

Resource links provided by NLM:

Further study details as provided by University of Manitoba:

Primary Outcome Measures:
  • Plasma cholesterol level [ Time Frame: 8 months ]
    Plasma cholesterol level will be assessed by GC

  • Plasma sitosterol level [ Time Frame: 8 months ]
    Plasma plant sterol assessment using GC

Secondary Outcome Measures:
  • Cholesterol absorption [ Time Frame: 4 month ]
    Use stable isotope technique to assess cholesterol absorption

  • Cholesterol synthesis [ Time Frame: 4 months ]
    Use of stable isotope to assess cholesterol synthesis.

Enrollment: 8
Study Start Date: April 2012
Estimated Study Completion Date: December 2016
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ezetimibe
Compare on and off ezetimibe
Drug: Ezetimibe
10mg ezetimibe/day, at least 4 months


Ages Eligible for Study:   16 Years to 99 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • confirmed diagnosis of homozygous sitosterolemia as established by genotyping and clinical parameters

Exclusion Criteria:

  • pregnant
  • intellectual disability
  • major infectious diseases
  • immunodeficiency
  • cancer
  • renal failure
  • diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01584206

Canada, Manitoba
Richardson Centre for Functional Foods and Nutraceuticals
Winnipeg, Manitoba, Canada, R3T 2N2
Sponsors and Collaborators
University of Manitoba
Principal Investigator: Semone B Myrie, PhD University of Manitoba
Study Chair: Peter J Jones, PhD University of Manitoba
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University of Manitoba Identifier: NCT01584206     History of Changes
Other Study ID Numbers: B2011:051
Study First Received: April 16, 2012
Last Updated: March 9, 2016

Keywords provided by University of Manitoba:
Plant sterol

Additional relevant MeSH terms:
Lipid Metabolism, Inborn Errors
Intestinal Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents processed this record on September 21, 2017